Question

I am a breastfeeding mother and i want to know if it is safe to use Metamizolo sodico [DCIT]? Is Metamizolo sodico [DCIT] safe for nursing mother and child? Does Metamizolo sodico [DCIT] extracts into breast milk? Does Metamizolo sodico [DCIT] has any long term or short term side effects on infants? Can Metamizolo sodico [DCIT] influence milk supply or can Metamizolo sodico [DCIT] decrease milk supply in lactating mothers?

Metamizolo sodico [DCIT] lactation summary

Metamizolo sodico [DCIT] usage has low risk in breastfeeding
  • DrLact safety Score for Metamizolo sodico [DCIT] is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of Metamizolo sodico [DCIT] may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that Metamizolo sodico [DCIT] may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of Metamizolo sodico [DCIT] low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using Metamizolo sodico [DCIT] We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Metamizolo sodico [DCIT] usage in lactation

Pirazolone derivative analgesic drug. Authorized and widely used drug in Europe and Latin America. Not approved in USA and UK since the 70’s because increased risk of rash, anaphylaxis and agranulocytosis (1 case out of 1 million) yet not confirmed in other settings. No untoward effects have been reported aside from a case of cyanosis in the 80’s. The American Academy of Pediatrics rates it as compatible with Breastfeeding.

Answer by DrLact: About Metamizolo sodico [DCIT] usage in lactation

Metamizolo sodico [DCIT] is not approved for marketing in the United States by the U.S. Food and Drug Administration or in Canada and many European countries because of its adverse reactions, including agranulocytosis. However, it is widely used in other countries during labor and breastfeeding.[1][2][3][4] After ingestion by the mother, Metamizolo sodico [DCIT] and its metabolites appear in breastmilk in rather large amounts. It is found in the blood and urine of breastfed infants and can cause pharmacological effects in the breastfed infant. One case of cyanotic episodes in a breastfed infant was attributed to Metamizolo sodico [DCIT] in breastmilk. The drug and metabolites are eliminated from the breastmilk by 48 hours after a dose and one manufacturer recommends no breastfeeding for 48 hours after a dose.[5] Safer alternatives are available for analgesia during breastfeeding.

Metamizolo sodico [DCIT] Side Effects in Breastfeeding

A 42-day-old breastfed infant had 2 cyanotic episodes within 30 minutes after his mother took 3 doses of Metamizolo sodico [DCIT] 500 mg orally, 18, 7 and 2 hours before the first episode. A third episode occurred 24 hours after admission to the hospital. Metamizolo sodico [DCIT] was detected in the mother's breastmilk 24 hours after the last dose and in the infant's serum and urine. No explanation could be found for the cyanotic episodes other than Metamizolo sodico [DCIT] and after suspending maternal Metamizolo sodico [DCIT] intake, no further episodes occurred in the infant up to age 3 years. The reaction is rated as possibly caused by Metamizolo sodico [DCIT] in breastmilk.[6] In a blinded study, mothers who were at least 3 days postpartum and requesting analgesia for postpartum uterine pain were given either 1 gram of Metamizolo sodico [DCIT] or placebo. The infants of mothers who received Metamizolo sodico [DCIT] cried fewer times and for shorter durations in the 14 hours after drug administration than the infants of mothers who received placebo. This effect was more apparent in infants who demand fed than in those who fed on a fixed schedule.[8] Although this study appears to demonstrate a pharmacologic effect in the infants from Metamizolo sodico [DCIT] in milk, there is no clear explanation for the change in infant behavior. A multicenter case-control study in Brazil compared 231 children who developed leukemia before 2 years of age with 411 children with various other nonmalignant diseases. Mothers were interviewed to ascertain their analgesic use during pregnancy and lactation. Nursing mothers who took Metamizolo sodico [DCIT] during the three months after delivery had a 2-fold risk of having a child with acute lymphocytic leukemia and a 3.87-fold risk in having rearrangement of the MLL gene in infants under one year of age.[9]

Synonyms of Metamizolo sodico [DCIT]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.